Wire · opportunities
GLP-1 use in US kids under-12 soars
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Use of GLP-1 drugs among American children under 12 has surged 300-fold since 2019 despite lack of FDA approval for this age group, driven by doctors prescribing these drugs off-label to combat severe obesity and related health issues. Clinical trials are underway to establish safety and efficacy for younger children, highlighting a regulatory and treatment gap in paediatric obesity management.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You face rising off-label use of GLP-1 drugs in young US children despite no FDA approval, creating both a market gap and regulatory tension you can navigate for early market entry or clinical alignment. Pressure mounts for official approval and safety data, so position your product to meet emerging clinical needs ahead of regulation.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics